For a long time, it was believed that endocrine therapy mainly induces apoptosis or suppresses the proliferation of cancer cells, until the benefit effects of these anti-ER therapeutics were revealed to inhibit the ER-negative cancers. The gene discussed is ESR1; the disease is cancer.